SENTI news

Senti Biosciences, Inc. filed an exhibit for a Senior Secured Convertible Note, with a maturity date of November 23, 2026. The document outlines hybrid payment terms consisting of cash, common stock, or a combination of both.

Senti Biosciences and its shareholders amended an existing securities purchase agreement to add a new investor, NSG BioInnovation Fund, L.P., and to authorize additional capital investments. This corporate action maintains Senti's capital raising capabilities during a strategic merger process.

The company executed a definitive agreement and plan of merger with Celadon Partners SPV 35 Limited, along with specified affiliates, defining terms for a corporate restructuring effective in July 2026.

Senti Holdings Inc. issued senior secured convertible notes requiring 200% repayment of principal at maturity. The offering provides capital financing with conversion rights, typical for biotech companies seeking non-dilutive funding.